Pharmaceutical Technology

FEBRUARY 23, 2023

Quotient Sciences supported a standalone DCS classification and formulation development package. A recent example of this was for a compound at the candidate selection stage. Permeability was high and solubility at 24 hours in intestinal buffer was less than the expected therapeutic dose, so solubility was classified as “low”.

Drug Development 98

Drug Development Compounding Dosage Packaging 98

Pharmaceutical Technology

FEBRUARY 9, 2023

Container Closure Integrity Testing (CCIT) is used to evaluate the ability of a pharmaceutical’s primary packaging to protect the sterility of its contents. On a regular basis, pharmaceutical manufacturers are performing CCIT during commercial production to ensure that packaging processes are operating as they should.

Packaging 52

Packaging Pharmaceutical Manufacturing Communication Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 15, 2023

While Catalent Inc and PCI Pharma Services are in charge of the solid dose and packaging of Lupkynis, Lonza is manufacturing the small molecule API. Vetter Pharma-Fertigung GmbH & Co KG is conducting the parenteral manufacture and packaging for Trulicity. Please check your email to download the Report.

Labelling 52

Labelling Packaging Communication Diabetes 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Compared to other dosage forms, tablets are simpler to manufacture, package, and transport. Tablet manufacturing, which is the most common OSD form, takes an API dry powder ingredient and compresses it to form tablets, which can be coated or uncoated. Please check your email to download the Webinar.

Dosage 52

Dosage Pharmaceutical Manufacturing Packaging Communication 52

Pharmaceutical Technology

JANUARY 6, 2023

The preparation of a semi-solid dosage form – from formulation and development, to scale-up, commercial manufacturing, and packaging – should ideally take place under one roof in a contiguous, end-to-end workflow to avoid unnecessary equipment and process changes. Please check your email to download the Whitepaper.

Dosage 52

Dosage Packaging Communication 52

Pharmaceutical Technology

NOVEMBER 28, 2022

We source as much of the materials as we possibly can locally, even packaging,” he notes. When we need new packaging, it is really simple to get and it is quick. “We have the skills. Wherever we can do it locally, we do. It generally does speed up supply; things get to the factory quicker. Printing is done in Glasgow.

Hospitals 52

Hospitals Packaging Medical Schools Documentation 52

Pharmaceutical Technology

JANUARY 12, 2023

That would not allow sufficient time to manufacture, package and distribute before half of the content was degraded. Solid state reactions occur much more slowly than liquid interactions. A great example is aspirin. Its half-life is only 50 hours if prepared as a solution. That is the reason aspirin is only sold as a solid.

Packaging 52

Packaging Communication Vaccines 52

Pharmaceutical Technology

NOVEMBER 30, 2022

A vitally important assay used across various stages of drug development and manufacturing, container closure integrity testing (CCIT) involves evaluating packaging systems to determine their ability to protect the stability and sterility of pharmaceutical products. The evolution of CCIT. Please check your email to download the Webinar.

Drug Development 52

Drug Development Packaging Communication 52

Pharmaceutical Technology

FEBRUARY 7, 2023

They can also give their feedback on the design of the clinical trial, if the comparator reflects the standard of care, and if real-world evidence is part of the evidence requirement package.” Overall, it is never too soon to begin market access activities, but it can easily be too late. Please check your email to download the Case Study.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Inpatient Drug Pricing Packaging 52

Pharmaceutical Technology

FEBRUARY 27, 2023

Contract manufacturing organizations (CMOs) not only produce the active pharmaceutical ingredient (API) at the heart of a therapy, but are also responsible for the sterile manufacturing and packaging of liquid and inhalational drug constituents and packaging, depending on the needs of the particular therapy.

Packaging 52

Packaging Chemotherapy Labelling Communication 52